U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Substance Class Protein
Created
by admin
on Mon Mar 31 21:39:07 GMT 2025
Edited
by admin
on Mon Mar 31 21:39:07 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type
Sequence Type COMPLETE
Record UNII
6KA1906BLC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PINATUZUMAB VEDOTIN
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
ACD-22-VCMMAE
Preferred Name English
ACD22-VCMMAE
Code English
DCDT2980S
Code English
FCU2703
Code English
RO-5541072-000
Code English
ACD-22VCMMAE
Code English
pinatuzumab vedotin [INN]
Common Name English
ANTI-CD22-MONOMETHYL AURISTATIN E ANTIBODY-DRUG CONJUGATE
Common Name English
PINATUZUMAB VEDOTIN [USAN]
Common Name English
FCU-2703
Code English
RG-7593
Code English
IMMUNOGLOBULIN G1-KAPPA AURISTATIN E CONJUGATE, ANTI-(HOMO SAPIENS CD22 (SIALIC ACID BINDING IG-LIKE LECTIN 2, SIGLEC2, SIGLEC-2, BLYMPHOCYTE CELL ADHESION MOLECULE, BL-CAM, LEU-14)), HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO AURISTATIN E
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN SIALIC ACID-BINDING IMMUNOGLOBULIN-LIKE LECTIN 2) (HUMAN-MUS MUSCULUS MONOCLONAL MCDT2219A HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL MCDT2219A .KAPPA.-CHAIN, DIMER, THIOETHER WITH N-(((4-((N-(6-(3-MERCAPTO-
Systematic Name English
RO-5541072000
Code English
RO5541072-000
Code English
Pinatuzumab vedotin [WHO-DD]
Common Name English
DCDT-2980S
Code English
Code System Code Type Description
USAN
AB-128
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
ChEMBL
CHEMBL2109272
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
NCI_THESAURUS
C104167
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
CAS
1313706-14-7
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
FDA UNII
6KA1906BLC
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
ChEMBL
CHEMBL3301585
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
SMS_ID
100000174354
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
INN
9713
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
WIKIPEDIA
Pinatuzumab vedotin
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
DRUG BANK
DB15432
Created by admin on Mon Mar 31 21:39:07 GMT 2025 , Edited by admin on Mon Mar 31 21:39:07 GMT 2025
PRIMARY
From To
1_22 1_96
1_147 1_203
1_223 3_219
1_229 2_229
1_232 2_232
1_264 1_324
1_370 1_428
2_22 2_96
2_147 2_203
2_264 2_324
2_370 2_428
2_223 4_219
3_23 3_93
3_139 3_199
4_23 4_93
4_139 4_199
Glycosylation Link Type Site
N 1_300
N 2_300
Related Record Type Details
PINATUZUMAB VEDOTIN
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_223] [1_229] [1_232] [2_223] [2_229] [2_232] [3_219] [4_219] CYSTEINE Amount: Cysteinyl vedotin 6603L01WUR
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:CALCULATED CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966